COMPANY
Abcon Therapeutics
The Company’s first product, ATX101, is a fully humanized monoclonal antibody-drug conjugate (ADC) that targets CD6, an established T cell marker. From company website Source · Oct 12, 2026
NIH awards 2
- NIH award 1R41CA275639-01 FY2022: $402,680 awarded for that fiscal year; activity R41 (STTR); PI LIN, FENG C; recipient as written: ABCON THERAPEUTICS, INC., CLEVELAND, OH. Development of a novel antibody-drug conjug source ↗
- NIH award 1R41EY033243-01 FY2021: $255,388 awarded for that fiscal year; activity R41 (STTR); PI LIN, FENG C; recipient as written: ABCON THERAPEUTICS, INC., CLEVELAND, OH. Development of a new drug for treating auto source ↗